Cardiovascular effects and interaction with adrenoceptors of urapidil.
Urapidil is a novel antihypertensive agent, chemically related to uracil. Its cardiovascular profile was evaluated in a variety of pharmacological models. Urapidil caused a significant decrease of blood pressure in intact rats, both hypertensive (SHR) and normotensive (WKY), as well as in alpha-glucochloralose-anaesthetized cats. Reflex tachycardia was not observed. An analysis in pithed rats showed that urapidil is an alpha-adrenoceptor blocking drug with an obvious selectivity for postsynaptic alpha 1- over alpha 2-adrenoceptors. The alpha 1-adrenoceptor blocking potency proved quantitatively less than that of prazosin. Experiments on isolated aorta preparations and radioligand binding studies confirmed the selectivity of urapidil for alpha 1- over alpha 2-adrenoceptors. The involvement of urapidil with presynaptic alpha 2-adrenoceptors proved negligible. Urapidil proved to possess modest but significant beta 1-adrenoceptor blocking activity, accompanied by a certain degree of intrinsic sympathomimetic activity (TSA) at the level of the cardiac beta 1-adrenoceptors. No significant interaction with vascular beta 2-adrenoceptors was observed. High doses of urapidil caused pressor effects of a probably unspecific nature; neither alpha-adrenoceptors nor 5HT-receptors were involved. When injected into the vertebral artery of the cat, urapidil caused a significant central hypotensive effect which was different from that of clonidine and related drugs, since it could not be blocked by yohimbine (alpha 2-receptor antagonist). Similarly, the modest sedation produced by urapidil in mice remained uninfluenced by yohimbine. The urapidil molecule does not contain any stereoisomers. Accordingly, one and the same molecule possesses the following pharmacodynamic properties: postsynaptic alpha 1-adrenoceptor blockade; weak postsynaptic alpha 2-adrenoceptor blockade; modest but selective beta 1-adrenoceptor blockade with ISA; central hypotensive activity not mediated by central alpha 2-adrenoceptors.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001667:Binding, Competitive / Q000187:drug effects; D002415:Cats; D003000:Clonidine / Q000378:metabolism; D003655:Decerebrate State; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006591:Hexobarbital / Q000494:pharmacology; D066298:In Vitro Techniques; D007263:Infusions, Parenteral; D008297:Male; D008566:Membranes / Q000378:metabolism; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D011224:Prazosin / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011919:Rats, Inbred Strains; D011921:Rats, Inbred WKY; D011941:Receptors, Adrenergic / Q000187:drug effects*
D000959:Antihypertensive Agents; D010879:Piperazines; D011941:Receptors, Adrenergic; C015568:urapidil; D006591:Hexobarbital; D003000:Clonidine; D011224:Prazosin